2018年3月6日 » Lilly, Boehringer Ingelheim, SGLT-2 inhibitor (market), Chronic hear failure (CHF)
Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials
- EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure1,2
- EMPERIAL is part of the most comprehensive clinical trial programme of an SGLT2 inhibitor in chronic heart failure3,4
